CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Deferred Stock Units	Retained Earnings	Accumulated Other Comprehensive (Loss) Income	Treasury Stock
Balance beginning of period (in shares) at Dec. 31, 2021		106,878
Balance beginning of period at Dec. 31, 2021	$ 689,992	$ 10,688	$ 1,377,320	$ 5,719	$ 2,920,440	$ (53,484)	$ (3,570,691)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	193,965				193,965
Other comprehensive income (loss), net	6,136					6,136
Repurchases of common stock, net	(273,058)						(273,058)
Common stock issued under stock plans, including excess tax benefit (in shares)		125
Common stock issued under stock plans, including excess tax benefit	11,590	$ 12	11,583	(5)
Share-based compensation cost	11,173		11,122	51
Balance end of period (in shares) at Mar. 31, 2022		107,003
Balance end of period at Mar. 31, 2022	639,798	$ 10,700	1,400,025	5,765	3,114,405	(47,348)	(3,843,749)
Balance beginning of period (in shares) at Dec. 31, 2021		106,878
Balance beginning of period at Dec. 31, 2021	689,992	$ 10,688	1,377,320	5,719	2,920,440	(53,484)	(3,570,691)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	506,882
Other comprehensive income (loss), net	(27,410)
Balance end of period (in shares) at Sep. 30, 2022		107,095
Balance end of period at Sep. 30, 2022	475,999	$ 10,709	1,437,528	5,176	3,427,322	(80,894)	(4,323,842)
Balance beginning of period (in shares) at Mar. 31, 2022		107,003
Balance beginning of period at Mar. 31, 2022	639,798	$ 10,700	1,400,025	5,765	3,114,405	(47,348)	(3,843,749)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	131,979				131,979
Other comprehensive income (loss), net	(20,357)					(20,357)
Repurchases of common stock, net	(313,508)						(313,508)
Common stock issued under stock plans, including excess tax benefit (in shares)		72
Common stock issued under stock plans, including excess tax benefit	6,726	$ 7	7,779	(1,060)
Deferred stock units activity	0		(459)	459
Share-based compensation cost	12,370		12,364	6
Balance end of period (in shares) at Jun. 30, 2022		107,075
Balance end of period at Jun. 30, 2022	457,008	$ 10,707	1,419,709	5,170	3,246,384	(67,705)	(4,157,257)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	180,938				180,938
Other comprehensive income (loss), net	(13,189)					(13,189)
Repurchases of common stock, net	(166,585)						(166,585)
Common stock issued under stock plans, including excess tax benefit (in shares)		20
Common stock issued under stock plans, including excess tax benefit	4,879	$ 2	4,877
Share-based compensation cost	12,948		12,942	6
Balance end of period (in shares) at Sep. 30, 2022		107,095
Balance end of period at Sep. 30, 2022	$ 475,999	$ 10,709	1,437,528	5,176	3,427,322	(80,894)	(4,323,842)
Balance beginning of period (in shares) at Dec. 31, 2022	107,193	107,193
Balance beginning of period at Dec. 31, 2022	$ 608,737	$ 10,719	1,463,215	5,182	3,599,529	(77,796)	(4,392,112)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	214,054				214,054
Other comprehensive income (loss), net	1,181					1,181
Repurchases of common stock, net	(9,554)						(9,554)
Common stock issued under stock plans, including excess tax benefit (in shares)		128
Common stock issued under stock plans, including excess tax benefit	12,753	$ 13	12,765	(25)
Share-based compensation cost	13,930		13,923	7
Balance end of period (in shares) at Mar. 31, 2023		107,321
Balance end of period at Mar. 31, 2023	$ 841,101	$ 10,732	1,489,903	5,164	3,813,583	(76,615)	(4,401,666)
Balance beginning of period (in shares) at Dec. 31, 2022	107,193	107,193
Balance beginning of period at Dec. 31, 2022	$ 608,737	$ 10,719	1,463,215	5,182	3,599,529	(77,796)	(4,392,112)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	650,521
Other comprehensive income (loss), net	$ 2,905
Balance end of period (in shares) at Sep. 30, 2023	107,452	107,452
Balance end of period at Sep. 30, 2023	$ 1,297,407	$ 10,745	1,543,024	5,523	4,250,050	(74,891)	(4,437,044)
Balance beginning of period (in shares) at Mar. 31, 2023		107,321
Balance beginning of period at Mar. 31, 2023	841,101	$ 10,732	1,489,903	5,164	3,813,583	(76,615)	(4,401,666)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	224,236				224,236
Other comprehensive income (loss), net	2,950					2,950
Repurchases of common stock, net	(77)						(77)
Common stock issued under stock plans, including excess tax benefit (in shares)		57
Common stock issued under stock plans, including excess tax benefit	10,289	$ 6	10,283
Deferred stock units activity	0		(345)	345
Share-based compensation cost	15,362		15,356	6
Balance end of period (in shares) at Jun. 30, 2023		107,378
Balance end of period at Jun. 30, 2023	1,093,861	$ 10,738	1,515,197	5,515	4,037,819	(73,665)	(4,401,743)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	212,231				212,231
Other comprehensive income (loss), net	(1,226)					(1,226)
Repurchases of common stock, net	(35,301)						(35,301)
Common stock issued under stock plans, including excess tax benefit (in shares)		74
Common stock issued under stock plans, including excess tax benefit	12,618	$ 7	12,611
Share-based compensation cost	$ 15,224		15,216	8
Balance end of period (in shares) at Sep. 30, 2023	107,452	107,452
Balance end of period at Sep. 30, 2023	$ 1,297,407	$ 10,745	$ 1,543,024	$ 5,523	$ 4,250,050	$ (74,891)	$ (4,437,044)